Development of a defective interfering RNA based antiviral approach to treat infections by SARS-CoV-2 and emerging variants

Key facts

Disease
COVID-19
Known Financial Commitments (USD)
$603,914.24
Funder
National Health and Medical Research Council (NHMRC)
Principal Investigator
Assoc Prof David Harrich
Research Location
Australia
Lead Research Institution
QIMR Berghofer Medical Research Institute
Research Priority Alignment
N/A

Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

Specific therapy for severe disease caused by SARS-CoV-2 is limited. The ability of viruses to become resistant to a therapy may be obstacle for antiviral development. This project develops a unique platform, using virus-specific antiviral RNA, as a unique and possibly "antiviral-resistance" proof approach that could be deployed as a therapeutic for COVID-19 and also help to solve the challenge of viral pandemics from known and unknown viruses, especially other human pathogenic coronaviruses.